AKT1 and cancer: As reported by some authors4,5, Sema6D can affect the activation of extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) signaling pathways, which influences tumorigenesis, cancer cell proliferation, poor prognosis, and drug resistance.